Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.

MLA

Geissler, Edward K., et al. “Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.” Transplantation, vol. 100, no. 1, Jan. 2016, pp. 116–25. EBSCOhost, https://doi.org/10.1097/TP.0000000000000965.

APA

Geissler, E. K., Schnitzbauer, A. A., Zülke, C., Lamby, P. E., Proneth, A., Duvoux, C., Burra, P., Jauch, K.-W., Rentsch, M., Ganten, T. M., Schmidt, J., Settmacher, U., Heise, M., Rossi, G., Cillo, U., Kneteman, N., Adam, R., van Hoek, B., Bachellier, P., & Wolf, P. (2016). Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation, 100(1), 116–125. https://doi.org/10.1097/TP.0000000000000965

Chicago

Geissler, Edward K., Andreas A. Schnitzbauer, Carl Zülke, Philipp E. Lamby, Andrea Proneth, Christophe Duvoux, Patrizia Burra, et al. 2016. “Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.” Transplantation 100 (1): 116–25. doi:10.1097/TP.0000000000000965.